At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IDNA iShares Genomics Immunology and Healthcare ETF
Trading 09-11 09:33:18 EDT
38.21
+0.33
+0.87%
High38.21Low38.21Vol1.78K
Open38.21D1 Closing37.88Amplitude0.00%
Mkt Cap252.19MTradable Cap252.19MTotal Shares6.60M
T/O67.75KT/O Rate0.03%Tradable Shares6.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating
MT Newswires Live  ·  19:22
Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)
TIPRANKS  ·  16:20
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)
Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update
TIPRANKS  ·  13:57
Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update
The Race for the Next Big Weight-Loss Drug is On-and China Wants In
Dow Jones  ·  08:00
The Race for the Next Big Weight-Loss Drug is On-and China Wants In
Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million
Reuters  ·  05:53
Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million
Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement
Reuters  ·  04:16
Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement
Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.
Dow Jones  ·  02:40
Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
MT Newswires Live  ·  09-10 23:29
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program
MT Newswires Live  ·  09-10 22:29
Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program
Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD
TIPRANKS  ·  09-10 22:25
Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
GlobeNewswire  ·  09-10 21:30
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program
THOMSON REUTERS  ·  09-10 21:00
Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program
Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors
Dow Jones  ·  09-10 20:05
Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
GlobeNewswire  ·  09-10 19:33
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255
THOMSON REUTERS  ·  09-10 18:09
Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255
BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion
Reuters  ·  09-10 16:32
BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion
Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial
Dow Jones  ·  09-10 05:45
Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
MT Newswires Live  ·  09-09 23:58
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
Twist Bioscience initiated with a Sell at BWS Financial
TIPRANKS  ·  09-09 21:30
Twist Bioscience initiated with a Sell at BWS Financial
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
GlobeNewswire  ·  09-09 20:30
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
No data available

Introduction

Company Name.
iShares Genomics Immunology and Healthcare ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
Issue price:
--